Hemab
Mattias Häger, PhD, MSc, serves as a Scientific Director at Hemab. He has more than a decade of experience within early drug discovery with a focus on translational in vivo pharmacology and experience in animal model generation, gene expression and editing, and assay development. Most recently, Mattias served as a Principal Scientist and Project Manager at LEO Pharma, with previous experience at Zealand Pharma and Novo Nordisk, where he worked in the Hemophilia Pharmacology department. He is the author of more than 10 scientific publications and received his MSc from the University of Gothenburg and PhD from Lund University.
This person is not in any offices
Hemab
Hemab Therapeutics ApS is an emerging biotech company supported by Novo Holdings A/S with the aim of developing novel treatments for rare and underserved bleeding disorders. Based in Copenhagen, the company is led by a team of drug developers and scientists with deep expertise in haemophilia. Hemab has exclusive licences to state-of-the-art antibody technologies from both Novo Nordisk A/S and Genmab A/S.